Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
about
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusSodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice.Efficacy of canagliflozin combined with antidiabetic drugs in treating type 2 diabetes mellitus: Meta-analysis of randomized control trials.Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus.Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity.Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitusCirculating SerpinB1 levels and clinical features in patients with type 2 diabetes.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol).Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesSodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Adverse Effects Associated With Newer Diabetes Therapies.SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.Efficacy and safety of canagliflozin in type 2 diabetes mellitus: systematic review of randomized controlled trials.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.Cardiovascular safety of therapies for type 2 diabetes.Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.Obesity as a risk factor for Alzheimer's disease: weighing the evidence.Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet.Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center.Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label,Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events.Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
P2860
Q26777994-0E1909F9-4537-4F74-8B95-762BF45CC58DQ33626249-7CFFB5F8-4F64-4131-A861-A5EFC31900EEQ33871321-D8A4F664-4DC1-4253-8CA5-2FC63620666EQ34726437-734CB445-38E0-4E4D-B22F-1F7A74A90A3FQ35852679-4E1431FA-9535-4F32-82D7-361E9E3360DEQ36058592-74DB4C75-C7A9-4961-9106-A4BEAE034122Q36059244-B58B89C8-8B25-4216-B68C-1E101F3056E5Q36144090-B12DE616-F796-443E-BAA7-1D2AF0300979Q36316732-4C48FFC5-127C-4921-8B0E-557926291941Q36813327-7E9CBE32-A1B4-4745-885D-33E7413B2134Q37018165-6C38A02D-1B4C-4219-BBA3-2F2313BACD80Q37454408-9B2050EA-A1D1-4C29-AB06-875A79A83612Q37672448-85AD762F-E6CE-4D79-B5DF-76BBFFD887DAQ37737454-772D8D72-5A9C-4998-B81C-0D8434E1CF20Q37741752-3D141C5D-77C3-4BC3-B85D-00BAB91CE107Q38250445-F3F5A469-5C0B-4D2A-9B05-AC2A80484CA9Q38365957-79D118FD-A8D9-4A2A-98CA-1DCE9B2D368AQ38468017-1880B8D0-82D8-44F5-9745-35FDFBF3B8ABQ38546214-D27B9BE6-1A40-4A86-B764-E729C2CD14CFQ38654762-DB9AAB4C-C659-471A-B8C5-B9C5301D702CQ38662950-E9862C36-0AE1-4505-83D7-0336C234BE4CQ38663903-65016477-6176-4C98-8C92-C1CF2D3B76C1Q38842559-97F6A397-6AB3-4F5C-8FC6-D137B0672819Q38940175-7E347ACF-2726-4482-87AC-232FAA0B3D9BQ38960547-B382FADC-C757-4835-902F-DE628BCA51A5Q40363925-686F3FFB-7856-4F04-8A54-31F801580B36Q41258175-7942D44A-3336-46C0-9D6C-FD5FC3A805CBQ41986529-0103CB93-2BC6-4B71-A1B2-B75B36585B35Q42974009-C711AFB7-195F-44EC-BC63-D5398BF38AE8Q47109328-94C33D1E-F813-4C68-A865-6800785B00E4Q47711358-A0E9D0B2-5330-43EB-96D1-741921B2B072Q48147721-B95EEA87-6C2E-4133-A63D-00C923E0CACDQ48353746-DFF993C7-94EB-4726-B44A-31F1EA8D4249Q49963693-436CEDAB-44E2-4B59-8FA5-4DD533756C78Q51737719-3F631D42-2044-48E6-8659-10001ACAD743Q52665265-64135B12-10CE-476B-A120-1AA9D454EE48Q53551539-39515C4F-5F77-4B58-AD8C-6197549D0E2AQ55649893-765C1F49-3D90-46DD-B962-ECE52FAC644EQ58724925-4798DC06-1822-4A7C-A5C8-84E46A7EAA95
P2860
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Renal sodium glucose cotranspo ...... l data and mechanism of action
@ast
Renal sodium glucose cotranspo ...... l data and mechanism of action
@en
Renal sodium glucose cotranspo ...... l data and mechanism of action
@nl
type
label
Renal sodium glucose cotranspo ...... l data and mechanism of action
@ast
Renal sodium glucose cotranspo ...... l data and mechanism of action
@en
Renal sodium glucose cotranspo ...... l data and mechanism of action
@nl
prefLabel
Renal sodium glucose cotranspo ...... l data and mechanism of action
@ast
Renal sodium glucose cotranspo ...... l data and mechanism of action
@en
Renal sodium glucose cotranspo ...... l data and mechanism of action
@nl
P2860
P3181
P356
P1476
Renal sodium glucose cotranspo ...... l data and mechanism of action
@en
P2093
Yoshihito Fujita
P2860
P304
P3181
P356
10.1111/JDI.12214
P407
P577
2014-05-04T00:00:00Z